| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 |
|---|---|---|---|---|---|---|---|---|---|
Cash flow from operating activities: | |||||||||
Net loss | |||||||||
-19,390 | -10,086 | - | - | - | - | - | - | - | - |
Net loss | |||||||||
- | - | -6,003 | -6,526 | -4,790 | -6,833 | -9,406 | -7,422 | -4,486 | -1,352 |
Adjustments to reconcile net loss to net cash used in operating activities: | |||||||||
Recognition of credit loss on notes receivable | |||||||||
1,037 | - | - | - | - | - | - | - | - | - |
Loss on equity method investment | |||||||||
-439 | -2,293 | - | - | - | - | - | - | - | - |
Gain on revaluation of equity method investment | |||||||||
6,164 | - | - | - | - | - | - | - | - | - |
Depreciation and amortization | |||||||||
704 | 147 | 71 | 82 | 78 | 63 | - | - | - | - |
Vesting expense | |||||||||
2,250 | 1,124 | 2,298 | 165 | 871 | 723 | - | 0 | 0 | 0 |
Equity instruments issued for management, consulting, and other | |||||||||
484 | 335 | - | - | - | - | - | - | - | - |
Equity instruments issued for management and consulting | |||||||||
- | - | 359 | 721 | -6 | - | - | - | - | - |
Issuance of common stock in cashless warrant exercise | |||||||||
- | - | - | - | 0 | - | - | - | - | - |
Depreciation and amortization | |||||||||
- | - | - | - | - | - | 148 | 1 | 3 | 2 |
Equity instruments issued for management and consulting | |||||||||
- | - | - | - | - | 112 | 3,700 | 830 | 1,937 | 172 |
Equity instruments issued for management and consulting | |||||||||
- | - | - | - | - | - | 239 | 3,919 | 507 | 726 |
Capital contributions resulting from waivers of debt | |||||||||
- | - | - | - | - | - | - | 0 | 0 | 0 |
Amortization of debt discount | |||||||||
2,023 | 385 | - | - | 219 | 247 | 413 | 57 | 112 | 55 |
Gain from sale of marketable securities | |||||||||
- | - | 1 | - | - | - | - | - | - | - |
Gain on valuation of equity-linked instruments | |||||||||
-221 | -372 | - | - | - | - | - | - | - | - |
Gain on revaluation of cash advances to Helomics | |||||||||
1,222 | - | - | - | - | - | - | - | - | - |
Debt extinguishment costs | |||||||||
-581 | - | - | - | - | - | - | - | - | - |
Loss on goodwill and intangible impairment | |||||||||
8,870 | - | - | - | - | - | - | - | - | - |
Loss on fixed asset disposal | |||||||||
-1 | - | - | - | - | - | - | - | - | - |
Penalty on debt provision | |||||||||
- | - | - | - | 10 | 0 | - | - | - | - |
Loss on Sales of Equipment | |||||||||
- | - | - | - | -17 | 0 | - | - | - | - |
Gain (loss) from sale of marketable securities | |||||||||
- | - | - | 4 | 0 | - | - | - | - | - |
Loss (gain) on valuation of equity-linked financial instruments | |||||||||
- | - | - | - | - | 11 | 157 | -3 | -151 | 1,145 |
Changes in assets and liabilities: | |||||||||
Accounts receivable | |||||||||
-143 | 95 | 98 | 0 | -19 | -39 | 57 | -10 | 50 | -15 |
Inventories | |||||||||
-91 | -23 | -7 | 40 | -135 | 245 | -23 | 47 | 97 | 0 |
Prepaid expense and other assets | |||||||||
29 | -139 | 141 | -122 | 81 | 129 | 33 | -2 | 22 | 4 |
Accounts payable | |||||||||
365 | 305 | -79 | -430 | -1,544 | 1,132 | - | - | - | - |
Notes payable to shareholders | |||||||||
- | - | - | - | - | - | - | 0 | 0 | 0 |
Accounts payable | |||||||||
- | - | - | - | - | - | 429 | 421 | 71 | 411 |
Accrued expenses | |||||||||
1,285 | 493 | -870 | 791 | -2,415 | 1,594 | 776 | 1,039 | 92 | 297 |
Deferred revenue | |||||||||
17 | 16 | -1 | - | - | - | - | - | - | - |
Deferred revenue | |||||||||
- | - | - | 2 | 0 | -64 | 69 | 0 | - | - |
Net cash used in operating activities | |||||||||
-8,732 | -5,287 | -4,459 | -4,381 | - | - | - | - | -1,781 | -820 |
Cash flow from investing activities: | |||||||||
Proceeds from sale of marketable securities | |||||||||
- | - | 284 | - | - | - | - | - | - | - |
Net cash used in operating activities: | |||||||||
- | - | - | - | -7,487 | -3,371 | -3,855 | -1,184 | - | - |
Purchase of marketable securities | |||||||||
- | - | - | - | 0 | - | - | - | - | - |
Proceeds from sale of marketable securities | |||||||||
- | - | - | 571 | 0 | - | - | - | - | - |
Purchase of certificates of deposit | |||||||||
- | - | 3,084 | 1,100 | 0 | - | - | - | - | - |
Redemption of certificates of deposit | |||||||||
- | 244 | 2,940 | 1,000 | 0 | - | - | - | - | - |
Advances on notes receivable | |||||||||
975 | 1,123 | 1,737 | 0 | - | - | - | - | - | - |
Cash received from notes receivable | |||||||||
154 | - | - | - | - | - | - | - | - | - |
Cash received from Helomics acquisition | |||||||||
248 | - | - | - | - | - | - | - | - | - |
Purchase of fixed assets | |||||||||
5 | 177 | 45 | 32 | 32 | 101 | 162 | 0 | 0 | 0 |
Acquisition of intangibles | |||||||||
20 | 54 | 10 | 11 | 28 | 19 | 53 | 0 | 0 | 0 |
Net cash used in investing activities: | |||||||||
- | - | - | - | -60 | -121 | -216 | 0 | - | - |
Proceeds from long-term and convertible debt | |||||||||
- | - | - | - | 250 | 1,500 | - | - | - | - |
Net cash used in investing activities | |||||||||
-599 | -1,110 | -1,653 | -422 | - | - | - | - | 0 | 0 |
Cash flow from financing activities: | |||||||||
Proceeds from debt issuance | |||||||||
2,690 | 2,185 | - | - | - | - | - | - | - | - |
Repayment of debt | |||||||||
1,154 | - | - | - | - | - | - | - | - | - |
Payment penalties | |||||||||
202 | - | - | - | - | - | - | - | - | - |
Proceeds from issuance of stock pursuant to equity line | |||||||||
319 | - | - | - | - | - | - | - | - | - |
Proceeds from exercise of warrants into common stock | |||||||||
5 | 650 | - | - | - | - | - | - | - | - |
Principal payments on debt | |||||||||
- | - | - | - | 933 | 305 | - | - | - | - |
Proceeds from long-term and convertible debt | |||||||||
- | - | - | - | - | - | 1,822 | 528 | 525 | 604 |
Repayment of convertible debt | |||||||||
- | - | - | - | - | - | - | 150 | 0 | 100 |
Principal payments on debt | |||||||||
- | - | - | - | - | - | 0 | 0 | 16 | 14 |
Net proceeds from issuance of preferred stock | |||||||||
- | - | - | - | 18 | 2,055 | 0 | - | - | - |
Restricted cash in escrow | |||||||||
- | - | - | - | - | - | - | - | - | 103 |
Proceeds from issuance of Series E convertible preferred stock | |||||||||
2,338 | - | 1,300 | - | - | - | - | - | - | - |
Issuance of common stock | |||||||||
5,323 | 2,959 | 3,814 | 1,712 | 13,051 | 157 | 2,337 | 695 | 1,386 | 219 |
Net cash provided by financing activities | |||||||||
9,320 | 5,794 | 5,114 | 1,712 | - | - | - | - | 1,895 | 813 |
Net decrease in cash | |||||||||
-11 | -604 | -997 | - | - | - | - | - | - | - |
Net cash provided by (used in) financing activities | |||||||||
- | - | - | - | 12,387 | 3,407 | 4,160 | 1,074 | - | - |
Net increase (decrease) in cash | |||||||||
- | - | - | - | 4,839 | -85 | - | - | - | - |
Net increase (decrease) in cash and cash equivalents | |||||||||
- | - | - | -3,092 | - | - | 88 | -109 | 113 | -7 |
Non-cash transactions | |||||||||
Common stock issued for accrued interest/bonus | |||||||||
- | - | - | - | - | 694 | - | - | - | - |
Bridge loan conversion into common stock | |||||||||
378 | - | - | - | - | - | 415 | 100 | 0 | - |
Forbearance settlement bridge loan | |||||||||
503 | - | - | - | - | - | - | - | - | - |
Warrants Issued | |||||||||
47 | - | - | - | - | - | - | - | - | - |
Warrants issued pursuant to debt issuance | |||||||||
180 | - | - | - | - | - | - | - | - | - |
Consideration given for acquisition of Helomics | |||||||||
26,711 | - | - | - | - | - | - | - | - | - |
Debt modification costs | |||||||||
162 | - | - | - | - | - | - | - | - | - |
Conversion of preferred stock to common stock | |||||||||
- | 6 | - | - | - | - | - | - | - | - |
Equity method investment – Helomics | |||||||||
- | 1,542 | - | - | - | - | - | - | - | - |
Licensing fee for TumorGenesis | |||||||||
- | 877 | - | - | - | - | - | - | - | - |
Interest paid on debt | |||||||||
146 | - | - | - | - | - | - | - | - | - |
Common stock issued for accrued interest/bonus | |||||||||
- | - | - | - | - | - | 402 | 106 | 24 | 0 |
Conversion of accounts payable to convertible debt | |||||||||
- | - | - | - | - | - | - | 0 | 89 | 457 |
Common stock issued to satisfy debt | |||||||||
- | - | - | - | 483 | 480 | 2,318 | 817 | 50 | 0 |
Stock/warrant issued to satisfy accounts payable/Liabilities | |||||||||
- | - | - | - | - | - | 100 | 418 | 20 | 0 |